RX-108 is under clinical development by Suzhou Neupharma and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RX-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RX-108 overview

RX-108 is under development for the treatment of primary hepatocellular carcinoma, locally advanced or metastatic solid tumors including recurrent glioblastoma multiforme and recurrent/metastatic head and neck squamous cell carcinoma. It is administered intravenously and parenteraly. The drug candidate is a sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) inhibitor.

Suzhou Neupharma overview

Suzhou Neupharma operates in pharmaceutical and healthcare industry. It is headquartered in China.

For a complete picture of RX-108’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.